PriceTargets.com logo

NASDAQ:MTEM - Molecular Templates Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $6.75
  • Forecasted Upside: 519.27 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.09 As of 05/18/2022 05:00 PM ET
▼ -0.08 (-6.84%)

This chart shows the closing price for MTEM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Molecular Templates Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MTEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MTEM

Analyst Price Target is $6.75
▲ +519.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Molecular Templates in the last 3 months. The average price target is $6.75, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 519.27% upside from the last price of $1.09.

This chart shows the closing price for MTEM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Molecular Templates. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/24/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/13/2022Stifel NicolausLower Price Target$11.00 ➝ $9.00Medium
3/30/2022BarclaysLower Price TargetOverweight$8.00 ➝ $4.50Medium
12/3/2021BarclaysReiterated RatingBuy$8.00N/A
4/21/2021Bank of AmericaInitiated CoverageBuy$12.00High
4/15/2021OppenheimerLower Price TargetOutperform$18.00 ➝ $13.00Medium
4/6/2021Jefferies Financial GroupBoost Price Target$18.00 ➝ $20.00High
2/1/2021UBS GroupInitiated CoverageNeutral$13.00Low
9/8/2020Jefferies Financial GroupInitiated CoverageBuy$21.00High
8/7/2020OppenheimerReiterated RatingBuyHigh
6/17/2020OppenheimerReiterated RatingBuy$22.00Medium
5/12/2020OppenheimerBoost Price TargetOutperform$16.00 ➝ $22.00High
3/25/2020Stifel NicolausInitiated CoverageBuy$19.00Low
2/27/2020BarclaysInitiated CoverageOverweight$22.00High
11/13/2019CowenReiterated RatingBuyHigh
8/13/2019CowenReiterated RatingBuyMedium
4/29/2019UBS GroupInitiated CoverageBuy ➝ Buy$12.00High
3/31/2019CowenReiterated RatingBuyLow
12/11/2018CIBCInitiated CoverageOutperform ➝ Outperform$15.00Medium
12/10/2018OppenheimerInitiated CoverageOutperform$15.00 ➝ $15.00High
12/10/2018LADENBURG THALM/SH SHReiterated RatingBuy$15.00High
11/20/2018CowenInitiated CoverageOutperformMedium
11/15/2018Evercore ISIInitiated CoverageOutperformHigh
10/8/2018LaidlawInitiated CoverageBuy ➝ Buy$18.00Medium
8/3/2017LADENBURG THALM/SH SHInitiated CoverageBuy ➝ Buy$10.00High
8/3/2017Stifel NicolausReiterated RatingHold$0.40Low
(Data available from 5/19/2017 forward)

News Sentiment Rating

0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/19/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Molecular Templates logo
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases. The company primarily develops a pipeline of therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT-5111, an ETB candidate that is in Phase I clinical trial for the treatment of HER2-positive cancers; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory myeloma patients; and MT-6402 in that is in Phase I clinical trial for PD-1/PD-L1 antibody relapsed/refractory patients. Its pipeline of ETBs in development for other targets, including CTLA-4, TIGIT, TROP2, BCMA, SLAMF-7, and CD45. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Read More

Today's Range

Now: $1.09
Low: $1.07
High: $1.17

50 Day Range

MA: $2.32
Low: $1.17
High: $3.45

52 Week Range

Now: $1.09
Low: $1.07
High: $9.38

Volume

239,536 shs

Average Volume

201,556 shs

Market Capitalization

$61.37 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Molecular Templates?

The following equities research analysts have issued reports on Molecular Templates in the last twelve months: Barclays PLC, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for MTEM.

What is the current price target for Molecular Templates?

0 Wall Street analysts have set twelve-month price targets for Molecular Templates in the last year. Their average twelve-month price target is $6.75, suggesting a possible upside of 519.3%.
View the latest price targets for MTEM.

What is the current consensus analyst rating for Molecular Templates?

Molecular Templates currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MTEM will outperform the market and that investors should add to their positions of Molecular Templates.
View the latest ratings for MTEM.

How do I contact Molecular Templates' investor relations team?

Molecular Templates' physical mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company's listed phone number is (512) 869-1555 and its investor relations email address is [email protected] The official website for Molecular Templates is www.mtem.com. Learn More about contacing Molecular Templates investor relations.